Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery

被引:15
|
作者
Li, Changhui [1 ]
Shen, Yinchen [1 ]
Hu, Fang [1 ]
Chu, Tianqing [1 ]
Yang, Xiaohua [2 ]
Shao, Jinchen [3 ]
Zheng, Xiaoxuan [1 ]
Xu, Jianlin [1 ]
Zhang, Hai [1 ]
Han, Baohui [1 ]
Zhong, Hua [1 ]
Zhang, Xueyan [1 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm, 241 West HuaihaiRd, Shanghai 200030, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Cent Lab, 241 West HuaihaiRd, Shanghai 200030, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pathol, 241 West HuaihaiRd, Shanghai 200030, Peoples R China
关键词
Lung adenocarcinoma; EGFR; Micropapillary; Brain metastases; Surgical resection; HISTOLOGIC SUBTYPE; CANCER PATIENTS; CLASSIFICATION; PROGNOSIS; IMPACT; CHEMOTHERAPY; RISK;
D O I
10.1016/j.lungcan.2020.01.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The role of micropapillary pattern (MIP) in EGFR-mutated NSCLC patients with brain metastases (BM) after complete surgical resection still remains unclear. Therefore, a retrospective study was conducted to evaluate the role of MIP in those patients. Methods: This study included 332 stage I-III patients with EGFR-mutant lung adenocarcinoma and complete resection. Patients were classified in four groups: the MIP-positive patients without BM development, the MIP-negative patients without BM development, the MIP-positive patients with BM development and the MIP-negative patients with BM development. Intracranial disease-free survival (iDFS), systemic disease-free survival (DFS) and overall survival (OS) were evaluated. Results: The median OS in the whole group was 70 months. The patients with MIP show inferior DFS (13 months vs. 22 months; P < 0.001) and OS (56 months vs. 74 months; P < 0.001). Furthermore, BM development was more likely to be found in patients with MIP (P = 0.001). In addition, the MIP-positive patients showed a significantly shorter iDFS compared with MIP-negative patients (14.5 months vs. 26 months; P < 0.001). Furthermore, the MIP-positive patients had significantly inferior iDFS in both BM as first line development groups (13 months vs. 19 months; P < 0.001) and BM as non-first line development groups (18 months vs. 33 months; P = 0.007). Conclusions: MIP was related to the earlier recurrence and shortened survival time. In addition, MIP was an independent poor prognostic factor for the increase of BM rate and the shortened time of BM development after surgery.
引用
收藏
页码:72 / 77
页数:6
相关论文
共 50 条
  • [31] ERLOTINIB VERSUS RADIATION THERAPY FOR BRAIN METASTASES IN PATIENTS WITH EGFR-MUTANT LUNG ADENOCARCINOMA
    Gerber, Naamit K.
    Yamada, Yoshiya
    Shi, Weiji
    Zhang, Zhigang
    Riely, Gregory
    Beal, Kathryn
    Yu, Helena A.
    Chan, Timothy A.
    Rimner, Andreas
    Wu, Abraham J.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S902 - S902
  • [32] Optimal intervention timing for craniocerebral radiotherapy in EGFR mutant lung adenocarcinoma patients with brain metastases
    Deng, Guangchuan
    Zhang, Qunxing
    Fan, Jing
    Zhao, Chenran
    Jiao, Hui
    Li, Zhenxiang
    BMC CANCER, 2024, 24 (01)
  • [33] First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma
    Chen, Yongshun
    Yang, Jing
    Li, Xue
    Hao, Daxuan
    Wu, Xiaoyuan
    Yang, Yuanyuan
    He, Chunyu
    Wang, Wen
    Wang, Jianhua
    CANCER SCIENCE, 2016, 107 (12) : 1800 - 1805
  • [34] Erlotinib with pemetrexed/cisplatin for patients with EGFR wild-type lung adenocarcinoma with brain metastases
    Zhang, Yalei
    Yang, Haihong
    Yang, Xinyun
    Deng, Qiuhua
    Zhao, Meilin
    Xu, Xin
    He, Jianxing
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (03) : 449 - 453
  • [35] Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma
    Iuchi, T.
    Shingyoji, M.
    Sakaida, T.
    Hatano, K.
    Nagano, O.
    Itakura, M.
    Kageyama, H.
    Yokoi, S.
    Hasegawa, Y.
    Kawasaki, K.
    Iizasa, T.
    LUNG CANCER, 2013, 82 (02) : 282 - 287
  • [36] A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation
    Haihong Yang
    Dongyun He
    Fengnan Wang
    Qiuhua Deng
    Zixian Xie
    Clinical & Experimental Metastasis, 2020, 37 : 391 - 399
  • [37] Evaluation of Lung Specific GPA Score in Adenocarcinoma Patients with Brain Metastasis and EGFR Activating Mutation
    Kao, William
    Dugue, Audrey
    Do, Pascal
    Dubos, Catherine
    Lerouge, Delphine
    Danhier, Serge
    Richard, Nicolas
    Geryaisl, Radj
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1193 - S1193
  • [38] Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients
    Sun, Yan
    Yu, Xinmin
    Shi, Xun
    Hong, Wei
    Zhao, Jun
    Shi, Lei
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2014, 12
  • [39] Use of thyroid transcription factor 1 and napsin A to predict local failure and survival after Gamma Knife radiosurgery in patients with brain metastases from lung adenocarcinoma
    Roh, Haewon
    Lee, Sung Yong
    Lee, Jinhwan
    Hwang, Soon -Young
    Kim, Jong Hyun
    JOURNAL OF NEUROSURGERY, 2022, 138 (03) : 663 - 673
  • [40] Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients
    Yan Sun
    Xinmin Yu
    Xun Shi
    Wei Hong
    Jun Zhao
    Lei Shi
    World Journal of Surgical Oncology, 12